28 / 63
Vaishnavi A, et al. Nature Medicine 2013; Drilon A et al, NEJM 2018
A shift of paradigm : ‘One drug fits all’
molecular alterations shared in several cancers
NTRK: neurotropic tropomyosin receptor kinase
2017
Aprobación de fármacos en base
a la alteración molecular
17 tipos
tumorales
ORR 76%
Larotrectinib